Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASTIVA
NCT06330038Phase 4Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of propofol in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Recurrence Free Survival at 3 years. Started Aug 2024; status: recruiting.
02
Drugs
propofol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06330038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06330038.